Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review
Aims To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations. Methods A scoping review was performed according to the Cochrane Collaboration and JBI and reported following the PRISMA‐ScR. Systematic searches on electronic...
Saved in:
| Published in | British journal of clinical pharmacology Vol. 90; no. 2; pp. 528 - 547 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
01.02.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0306-5251 1365-2125 1365-2125 |
| DOI | 10.1111/bcp.15933 |
Cover
Loading…
| Abstract | Aims
To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations.
Methods
A scoping review was performed according to the Cochrane Collaboration and JBI and reported following the PRISMA‐ScR. Systematic searches on electronic databases were conducted to integrate the current evidence on ciprofloxacin's pharmacokinetics. The quality of the included studies was assessed using ClinPK's checklist.
Results
The search yielded 55 relevant studies. Within the traditional pharmacokinetics studies (n = 46), 86 profiles were examined (72 involving healthy patients and 14 with various clinical conditions). Oral ciprofloxacin's pharmacokinetics were influenced by covariates such as drug interactions (ferrous ions, calcium carbonate, diclofenac and itraconazole), food interactions (calcium‐rich foods), elderly populations and renal impairment. Notably, variability in pharmacokinetic parameters existed among subjects, regardless of their health status, underscoring the need for comprehensive population descriptions. Population pharmacokinetic studies (n = 9) identified significant covariates for hospitalized patients, such as creatinine clearance, plasma bicarbonate, estimated glomerular filtration rate, renal replacement therapy, age, sex, total bilirubin, fat‐free mass, dietary factors in renal disease, rifampicin for clearance models and body weight for volume of distribution models. Most pharmacokinetic/pharmacodynamic assessments concluded that 1200 mg/day provides a high probability of target attainment for bacteria with minimum inhibitory concentration <0.5 mg L−1, aiming for an area under the curve for 24 h/minimum inhibitory concentration >125 h.
Conclusions
This study offers a comprehensive overview regarding oral ciprofloxacin's pharmacokinetics across various health conditions. It highlights the complexities of ciprofloxacin's pharmacokinetics, emphasizing the importance of considering multiple factors in dose adjustments. |
|---|---|
| AbstractList | To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations.
A scoping review was performed according to the Cochrane Collaboration and JBI and reported following the PRISMA-ScR. Systematic searches on electronic databases were conducted to integrate the current evidence on ciprofloxacin's pharmacokinetics. The quality of the included studies was assessed using ClinPK's checklist.
The search yielded 55 relevant studies. Within the traditional pharmacokinetics studies (n = 46), 86 profiles were examined (72 involving healthy patients and 14 with various clinical conditions). Oral ciprofloxacin's pharmacokinetics were influenced by covariates such as drug interactions (ferrous ions, calcium carbonate, diclofenac and itraconazole), food interactions (calcium-rich foods), elderly populations and renal impairment. Notably, variability in pharmacokinetic parameters existed among subjects, regardless of their health status, underscoring the need for comprehensive population descriptions. Population pharmacokinetic studies (n = 9) identified significant covariates for hospitalized patients, such as creatinine clearance, plasma bicarbonate, estimated glomerular filtration rate, renal replacement therapy, age, sex, total bilirubin, fat-free mass, dietary factors in renal disease, rifampicin for clearance models and body weight for volume of distribution models. Most pharmacokinetic/pharmacodynamic assessments concluded that 1200 mg/day provides a high probability of target attainment for bacteria with minimum inhibitory concentration <0.5 mg L
, aiming for an area under the curve for 24 h/minimum inhibitory concentration >125 h.
This study offers a comprehensive overview regarding oral ciprofloxacin's pharmacokinetics across various health conditions. It highlights the complexities of ciprofloxacin's pharmacokinetics, emphasizing the importance of considering multiple factors in dose adjustments. To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations.AIMSTo map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations.A scoping review was performed according to the Cochrane Collaboration and JBI and reported following the PRISMA-ScR. Systematic searches on electronic databases were conducted to integrate the current evidence on ciprofloxacin's pharmacokinetics. The quality of the included studies was assessed using ClinPK's checklist.METHODSA scoping review was performed according to the Cochrane Collaboration and JBI and reported following the PRISMA-ScR. Systematic searches on electronic databases were conducted to integrate the current evidence on ciprofloxacin's pharmacokinetics. The quality of the included studies was assessed using ClinPK's checklist.The search yielded 55 relevant studies. Within the traditional pharmacokinetics studies (n = 46), 86 profiles were examined (72 involving healthy patients and 14 with various clinical conditions). Oral ciprofloxacin's pharmacokinetics were influenced by covariates such as drug interactions (ferrous ions, calcium carbonate, diclofenac and itraconazole), food interactions (calcium-rich foods), elderly populations and renal impairment. Notably, variability in pharmacokinetic parameters existed among subjects, regardless of their health status, underscoring the need for comprehensive population descriptions. Population pharmacokinetic studies (n = 9) identified significant covariates for hospitalized patients, such as creatinine clearance, plasma bicarbonate, estimated glomerular filtration rate, renal replacement therapy, age, sex, total bilirubin, fat-free mass, dietary factors in renal disease, rifampicin for clearance models and body weight for volume of distribution models. Most pharmacokinetic/pharmacodynamic assessments concluded that 1200 mg/day provides a high probability of target attainment for bacteria with minimum inhibitory concentration <0.5 mg L-1 , aiming for an area under the curve for 24 h/minimum inhibitory concentration >125 h.RESULTSThe search yielded 55 relevant studies. Within the traditional pharmacokinetics studies (n = 46), 86 profiles were examined (72 involving healthy patients and 14 with various clinical conditions). Oral ciprofloxacin's pharmacokinetics were influenced by covariates such as drug interactions (ferrous ions, calcium carbonate, diclofenac and itraconazole), food interactions (calcium-rich foods), elderly populations and renal impairment. Notably, variability in pharmacokinetic parameters existed among subjects, regardless of their health status, underscoring the need for comprehensive population descriptions. Population pharmacokinetic studies (n = 9) identified significant covariates for hospitalized patients, such as creatinine clearance, plasma bicarbonate, estimated glomerular filtration rate, renal replacement therapy, age, sex, total bilirubin, fat-free mass, dietary factors in renal disease, rifampicin for clearance models and body weight for volume of distribution models. Most pharmacokinetic/pharmacodynamic assessments concluded that 1200 mg/day provides a high probability of target attainment for bacteria with minimum inhibitory concentration <0.5 mg L-1 , aiming for an area under the curve for 24 h/minimum inhibitory concentration >125 h.This study offers a comprehensive overview regarding oral ciprofloxacin's pharmacokinetics across various health conditions. It highlights the complexities of ciprofloxacin's pharmacokinetics, emphasizing the importance of considering multiple factors in dose adjustments.CONCLUSIONSThis study offers a comprehensive overview regarding oral ciprofloxacin's pharmacokinetics across various health conditions. It highlights the complexities of ciprofloxacin's pharmacokinetics, emphasizing the importance of considering multiple factors in dose adjustments. Aims To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations. Methods A scoping review was performed according to the Cochrane Collaboration and JBI and reported following the PRISMA‐ScR. Systematic searches on electronic databases were conducted to integrate the current evidence on ciprofloxacin's pharmacokinetics. The quality of the included studies was assessed using ClinPK's checklist. Results The search yielded 55 relevant studies. Within the traditional pharmacokinetics studies (n = 46), 86 profiles were examined (72 involving healthy patients and 14 with various clinical conditions). Oral ciprofloxacin's pharmacokinetics were influenced by covariates such as drug interactions (ferrous ions, calcium carbonate, diclofenac and itraconazole), food interactions (calcium‐rich foods), elderly populations and renal impairment. Notably, variability in pharmacokinetic parameters existed among subjects, regardless of their health status, underscoring the need for comprehensive population descriptions. Population pharmacokinetic studies (n = 9) identified significant covariates for hospitalized patients, such as creatinine clearance, plasma bicarbonate, estimated glomerular filtration rate, renal replacement therapy, age, sex, total bilirubin, fat‐free mass, dietary factors in renal disease, rifampicin for clearance models and body weight for volume of distribution models. Most pharmacokinetic/pharmacodynamic assessments concluded that 1200 mg/day provides a high probability of target attainment for bacteria with minimum inhibitory concentration <0.5 mg L−1, aiming for an area under the curve for 24 h/minimum inhibitory concentration >125 h. Conclusions This study offers a comprehensive overview regarding oral ciprofloxacin's pharmacokinetics across various health conditions. It highlights the complexities of ciprofloxacin's pharmacokinetics, emphasizing the importance of considering multiple factors in dose adjustments. |
| Author | Lazo, Raul Edison Luna Deffert, Flávia Borba, Helena Hiemisch Lobo Carneiro, Jaqueline Pontarolo, Roberto Junkert, Allan Michael Campos, Michel Leandro |
| Author_xml | – sequence: 1 givenname: Allan Michael orcidid: 0000-0002-1168-241X surname: Junkert fullname: Junkert, Allan Michael organization: Federal University of Parana – sequence: 2 givenname: Raul Edison Luna orcidid: 0000-0002-3434-1239 surname: Lazo fullname: Lazo, Raul Edison Luna email: raulluna@ufpr.br organization: Federal University of Parana – sequence: 3 givenname: Flávia orcidid: 0000-0002-2188-9967 surname: Deffert fullname: Deffert, Flávia organization: Federal University of Parana – sequence: 4 givenname: Jaqueline orcidid: 0000-0002-2037-0215 surname: Carneiro fullname: Carneiro, Jaqueline organization: Federal University of Parana – sequence: 5 givenname: Helena Hiemisch Lobo orcidid: 0000-0001-9723-584X surname: Borba fullname: Borba, Helena Hiemisch Lobo organization: Federal University of Parana – sequence: 6 givenname: Michel Leandro orcidid: 0000-0002-7147-7637 surname: Campos fullname: Campos, Michel Leandro organization: Federal University of Parana – sequence: 7 givenname: Roberto orcidid: 0000-0002-7049-4363 surname: Pontarolo fullname: Pontarolo, Roberto email: pontarolo@ufpr.br organization: Federal University of Parana |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37850318$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMlOwzAQhi1URBc48AIoRzikteM4CzeoWFWJHuAcTbyAIbGDnVD69gRaOCDBaKS5fP9o5hujgbFGInRI8JT0NSt5MyUsp3QHjQhNWBiRiA3QCFOchCxiZIjG3j9jTChJ2B4a0jRjmJJshG6XT-Bq4PZFG9lq7gOrAuugCrhunFWVfQeuTdA3iK5qgwZaLU3rT4OzwHPbaPMYOPmm5Wof7SqovDzYzgl6uLy4n1-Hi7urm_nZIuQ0wTQkOWcJQMxUBjEps1TgKIEoKkshhYRMiVimMcZK5SJNKQjMAEAxUeYgBJd0go43e_v7Xjvp26LWnsuqAiNt54soS7OUkJwlPXq0RbuylqJonK7BrYvv_3vgZANwZ713Uv0gBBefbovebfHltmdnv1iu296GNa0DXf2XWOlKrv9eXZzPl5vEBzg-i1Q |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2024_e32571 crossref_primary_10_3390_antibiotics13090856 crossref_primary_10_3390_antibiotics13111011 |
| Cites_doi | 10.2165/00044011‐200929040‐00006 10.1128/AAC.29.1.62 10.1016/j.ijpharm.2008.12.026 10.1016/j.ijantimicag.2008.05.019 10.1038/psp.2013.14 10.1016/j.ijantimicag.2006.07.026 10.3389/fpubh.2022.1025633 10.1093/jac/33.1.103 10.1007/978‐3‐663‐01930‐5_17 10.1016/j.coph.2017.09.009 10.1016/S0399‐077X(05)81021‐2 10.1007/BF00606636 10.46658/JBIRM‐20‐01 10.1093/jac/20.4.575 10.1016/j.arcmed.2020.02.008 10.1111/j.1365‐2125.1991.tb05526.x 10.1002/j.1875‐9114.1986.tb03458.x 10.1016/j.exger.2014.05.013 10.1007/s40262‐015‐0236‐8 10.1128/AAC.41.7.1508 10.1097/ACO.0000000000000814 10.1128/AAC.35.7.1484 10.1128/AAC.39.5.1045 10.1002/jps.22259 10.1128/AAC.35.11.2352 10.1093/jac/26.suppl_B.61 10.7326/M18‐0850 10.1093/jac/dkr220 10.1016/j.ejpb.2017.10.019 10.1186/s13643‐023‐02178‐5 10.1128/AAC.35.5.1004 10.1007/s13181‐015‐0488‐6 10.3390/microorganisms9061158 10.1128/AAC.31.5.709 10.1128/AAC.26.5.741 10.1007/s00134‐015‐4032‐6 10.1128/AAC.37.10.2193 10.1128/AAC.27.3.375 10.1002/j.1875‐9114.1989.tb04152.x 10.1128/AAC.46.12.3724‐3730.2002 10.1093/jac/33.1.111 10.1093/jac/dkab275 10.1111/j.1365‐2125.1996.tb00059.x 10.1128/AAC.36.4.830 10.1093/jac/17.5.629 10.1128/AAC.38.9.2187 10.1038/clpt.1991.174 10.1186/s12879‐015‐1282‐4 10.1016/0924‐8579(95)00030‐6 10.1016/0009‐9236(95)90215‐5 10.1093/jac/dky485 10.1002/j.1552‐4604.1989.tb03260.x 10.1002/j.1552‐4604.1988.tb03202.x 10.3390/pharmaceutics14050965 10.1128/AAC.30.1.152 10.1023/A:1016212804288 10.1097/FPC.0b013e32834c6efd 10.1186/s13643-021-01626-4 10.1128/AAC.47.12.3789‐3794.2003 10.3109/14756360903373350 10.1128/AAC.31.6.915 10.1016/j.ejpb.2004.03.001 10.1007/BF01667843 10.1128/AAC.24.5.784 10.1161/CIRCULATIONAHA.109.914820 10.1016/j.chest.2018.04.036 10.1016/j.accpm.2022.101080 10.1128/AAC.39.9.2161 10.1007/s00228‐020‐02873‐5 10.3390/pharmaceutics13081156 10.4103/jcrsm.jcrsm_8_18 10.1016/j.ejps.2017.01.030 10.1002/bdd.748 10.2165/00003495‐199500492‐00094 10.1002/j.1552‐4604.1986.tb02938.x 10.3390/molecules25173843 10.1093/jac/dkq211 10.1159/000195216 |
| ContentType | Journal Article |
| Copyright | 2023 British Pharmacological Society. |
| Copyright_xml | – notice: 2023 British Pharmacological Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/bcp.15933 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2125 |
| EndPage | 547 |
| ExternalDocumentID | 37850318 10_1111_bcp_15933 BCP15933 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Scoping Review |
| GrantInformation_xml | – fundername: Brazilian National Council of Technological and Scientific Development (CNPq) – fundername: Brazilian Federal Agency for Support and Evaluation of Graduate Education within the Ministry of Education of Brazil funderid: 001 – fundername: Brazilian Federal Agency for Support and Evaluation of Graduate Education within the Ministry of Education of Brazil grantid: 001 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c3603-19c56aa45f8a41b87d026a22bbdedea8fd4e7400ff9d773ad05aaaf5db9addce3 |
| IEDL.DBID | DR2 |
| ISSN | 0306-5251 1365-2125 |
| IngestDate | Fri Jul 11 05:58:36 EDT 2025 Mon Jul 21 06:02:30 EDT 2025 Tue Jul 01 01:59:33 EDT 2025 Thu Apr 24 23:10:47 EDT 2025 Wed Jan 22 16:16:02 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | pharmacokinetics PK/PD popPK ciprofloxacin scoping review |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2023 British Pharmacological Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3603-19c56aa45f8a41b87d026a22bbdedea8fd4e7400ff9d773ad05aaaf5db9addce3 |
| Notes | Funding information This research did not receive funding from a specific fund. SourceType-Scholarly Journals-1 ObjectType-Feature-4 ObjectType-Undefined-1 content type line 23 ObjectType-Review-2 ObjectType-Article-3 |
| ORCID | 0000-0002-2188-9967 0000-0002-7147-7637 0000-0002-3434-1239 0000-0002-1168-241X 0000-0002-7049-4363 0000-0002-2037-0215 0000-0001-9723-584X |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.15933 |
| PMID | 37850318 |
| PQID | 2878711956 |
| PQPubID | 23479 |
| PageCount | 20 |
| ParticipantIDs | proquest_miscellaneous_2878711956 pubmed_primary_37850318 crossref_primary_10_1111_bcp_15933 crossref_citationtrail_10_1111_bcp_15933 wiley_primary_10_1111_bcp_15933_BCP15933 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2024 2024-02-00 20240201 |
| PublicationDateYYYYMMDD | 2024-02-01 |
| PublicationDate_xml | – month: 02 year: 2024 text: February 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2024 |
| References | 2018; 122 1987; 31 2013; 2 1995; 39 1986; 30 1984; 26 1997; 41 1991; 50 2018; 169 2008; 32 2003; 53 1985; 27 1993; 37 2010; 65 2021; 76 2010; 25 2018; 4 1987; 82 2017; 36 2020; 51 2002; 46 2006; 28 1986; 6 1994; 33 1986 2003; 47 2016; 42 2011; 66 2014; 57 1994; 38 2012; 22 2011; 123 1983; 24 2021; 9 2015; 15 2023; 12 1991; 35 2019; 74 2004; 47 1995; 57 1995; 12 1991; 31 1989; 9 1986; 14 2015; 11 2015; 54 1986; 17 2011; 32 2022; 41 2009; 371 1992; 36 2020; 33 2020; 76 1995; 6 2009; 29 1989; 29 2021; 13 1990; 20 2018; 154 2021; 10 1987; 20 2004; 51 2023 1990; 26 2022 1995; 49 2004; 58 1986; 26 1988; 28 2019 1986; 29 2022; 14 2020; 25 2022; 10 2013 2017; 101 2011; 100 1996; 42 e_1_2_11_70_1 e_1_2_11_72_1 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_78_1 e_1_2_11_57_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_74_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_76_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 Escobar Y (e_1_2_11_38_1) 2003; 53 e_1_2_11_83_1 e_1_2_11_60_1 e_1_2_11_81_1 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_66_1 e_1_2_11_47_1 e_1_2_11_68_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_62_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_64_1 e_1_2_11_85_1 e_1_2_11_17_1 e_1_2_11_15_1 e_1_2_11_59_1 e_1_2_11_19_1 e_1_2_11_50_1 e_1_2_11_71_1 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_56_1 e_1_2_11_77_1 Thai TS (e_1_2_11_2_1) 2023 e_1_2_11_58_1 e_1_2_11_79_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_73_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_54_1 e_1_2_11_75_1 e_1_2_11_7_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_49_1 e_1_2_11_82_1 Higgins JPT (e_1_2_11_18_1) 2022 e_1_2_11_61_1 e_1_2_11_80_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_67_1 Bashir F (e_1_2_11_30_1) 2004; 47 e_1_2_11_46_1 e_1_2_11_69_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_63_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_65_1 e_1_2_11_84_1 Hooper DC (e_1_2_11_3_1) 1987; 82 e_1_2_11_16_1 e_1_2_11_37_1 e_1_2_11_39_1 |
| References_xml | – volume: 14 issue: 5 year: 2022 article-title: Ciprofloxacin in patients undergoing extracorporeal membrane oxygenation (ECMO): a population pharmacokinetic study publication-title: Pharmaceutics – volume: 51 start-page: 292 issue: 4 year: 2004 end-page: 295 article-title: Pharmacokinetics of ciprofloxacin in the elderly publication-title: Respiration – volume: 20 start-page: 575 issue: 4 year: 1987 end-page: 583 article-title: Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients publication-title: Journal of Antimicrobial Chemotherapy. – volume: 36 start-page: 107 year: 2017 end-page: 113 article-title: Use of Monte Carlo simulation and considerations for PK‐PD targets to support antibacterial dose selection publication-title: Curr Opin Pharmacol – volume: 20 start-page: 33 issue: 1 year: 1990 end-page: 37 article-title: Caracteristiques pharmacocinetiques de la ciprofloxacine par voies orale et intraveineuse publication-title: Med mal Infect – volume: 47 start-page: 214 issue: 3 year: 2004 end-page: 217 article-title: Single‐dose pharmacokinetics study of ciprofloxacin after oral administration to the healthy volunteers publication-title: Biological Sciences—PJSIR – volume: 26 start-page: 222 issue: 3 year: 1986 end-page: 226 article-title: Single‐dose pharmacokinetics of Oral ciprofloxacin in patients with cystic fibrosis publication-title: The Journal of Clinical Pharmacology – volume: 76 start-page: 2906 issue: 11 year: 2021 end-page: 2913 article-title: Ciprofloxacin population pharmacokinetics during long‐term treatment of osteoarticular infections publication-title: J Antimicrob Chemother – volume: 25 start-page: 577 issue: 4 year: 2010 end-page: 589 article-title: Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects publication-title: J Enzyme Inhib Med Chem – volume: 26 start-page: 61 issue: suppl_B year: 1990 end-page: 67 article-title: Pharmacokinetics of fluoroquinolones in hepatic failure publication-title: Journal of Antimicrobial Chemotherapy – volume: 101 start-page: 100 year: 2017 end-page: 106 article-title: Food effect: the combined effect of media pH and viscosity on the gastrointestinal absorption of ciprofloxacin tablet publication-title: Eur J Pharm Sci – volume: 100 start-page: 22 issue: 1 year: 2011 end-page: 33 article-title: Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride publication-title: J Pharm Sci – volume: 29 start-page: 953 issue: 10 year: 1989 end-page: 955 article-title: Ciprofloxacin pharmacokinetics after a standard or high‐fat/high‐calcium breakfast publication-title: J Clin Pharmacol – volume: 41 issue: 3 year: 2022 article-title: Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study) publication-title: Anaesth Crit Care Pain Med – volume: 54 start-page: 783 issue: 7 year: 2015 end-page: 795 article-title: Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement publication-title: Clin Pharmacokinet – volume: 33 start-page: 103 issue: 1 year: 1994 end-page: 110 article-title: The comparative pharmacokinetics and tissue penetration of single‐dose ciprofloxacin 400 mg iv and 750 mg po publication-title: Journal of Antimicrobial Chemotherapy. – volume: 31 start-page: 915 issue: 6 year: 1987 end-page: 919 article-title: Pharmacokinetics of ciprofloxacin in cystic fibrosis publication-title: Antimicrob Agents Chemother – volume: 57 start-page: 107 year: 2014 end-page: 113 article-title: Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections publication-title: Exp Gerontol – volume: 37 start-page: 2193 issue: 10 year: 1993 end-page: 2199 article-title: Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers publication-title: Antimicrob Agents Chemother – volume: 2 issue: 4 year: 2013 article-title: Basic concepts in population modeling, simulation, and model‐based drug development‐part 2: introduction to pharmacokinetic modeling methods publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 65 start-page: 1725 issue: 8 year: 2010 end-page: 1732 article-title: Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection publication-title: J Antimicrob Chemother – volume: 22 start-page: 73 issue: 1 year: 2012 end-page: 77 article-title: PharmGKB summary: very important pharmacogene information for CYP1A2 publication-title: Pharmacogenet Genomics – volume: 13 issue: 8 year: 2021 article-title: No time dependence of ciprofloxacin pharmacokinetics in critically ill adults: comparison of individual and population analyses publication-title: Pharmaceutics – volume: 35 start-page: 1484 issue: 7 year: 1991 end-page: 1485 article-title: Effects of enzyme supplementation on oral absorption of ciprofloxacin in patients with cystic fibrosis publication-title: Antimicrob Agents Chemother – volume: 29 start-page: 275 issue: 4 year: 2009 end-page: 281 article-title: Pharmacokinetic interaction of ciprofloxacin with diclofenac publication-title: Clin Drug Investig – volume: 38 start-page: 2187 issue: 9 year: 1994 end-page: 2190 article-title: Effect of bismuth subsalicylate on ciprofloxacin bioavailability publication-title: Antimicrob Agents Chemother – volume: 28 start-page: 551 issue: 6 year: 2006 end-page: 559 article-title: Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose publication-title: Int J Antimicrob Agents – volume: 11 start-page: 342 issue: 3 year: 2015 end-page: 354 article-title: A review of the Toxicologic implications of obesity publication-title: J Med Toxicol – volume: 12 start-page: 413 issue: 3 year: 1995 end-page: 420 article-title: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability publication-title: Pharm Res – volume: 10 year: 2022 article-title: The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic publication-title: Front Public Health – volume: 31 start-page: 589 issue: 5 year: 1987 end-page: 593 article-title: Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis publication-title: Eur J Clin Pharmacol – volume: 76 start-page: 957 issue: 7 year: 2020 end-page: 967 article-title: Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients publication-title: Eur J Clin Pharmacol – year: 2022 – volume: 30 start-page: 152 issue: 1 year: 1986 end-page: 156 article-title: Pharmacokinetics of single‐dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis publication-title: Antimicrob Agents Chemother – volume: 41 start-page: 1508 issue: 7 year: 1997 end-page: 1511 article-title: Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS publication-title: Antimicrob Agents Chemother – volume: 74 start-page: 682 issue: 3 year: 2019 end-page: 690 article-title: Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose publication-title: J Antimicrob Chemother – volume: 33 start-page: 111 issue: 1 year: 1994 end-page: 118 article-title: Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin publication-title: Journal of Antimicrobial Chemotherapy – volume: 66 start-page: 1798 issue: 8 year: 2011 end-page: 1809 article-title: Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic‐pharmacodynamic analysis and Monte Carlo simulations publication-title: J Antimicrob Chemother – volume: 24 start-page: 784 issue: 5 year: 1983 end-page: 786 article-title: Pharmacokinetics and tissue penetration of ciprofloxacin publication-title: Antimicrob Agents Chemother – volume: 31 start-page: 709 issue: 5 year: 1987 end-page: 712 article-title: Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function publication-title: Antimicrob Agents Chemother – volume: 42 start-page: 632 issue: 5 year: 1996 end-page: 634 article-title: Lack of gender effect on ciprofloxacin pharmacokinetics in humans publication-title: Br J Clin Pharmacol – volume: 50 start-page: 498 issue: 5/1 year: 1991 end-page: 502 article-title: Interference of dairy products with the absorption of ciprofloxacin publication-title: Clinical Pharmacology & Therapeutics – year: 2019 – volume: 26 start-page: 741 issue: 5 year: 1984 end-page: 744 article-title: Multiple‐dose pharmacokinetics and safety of ciprofloxacin in normal volunteers publication-title: Antimicrob Agents Chemother – volume: 82 start-page: 12 issue: 4a year: 1987 end-page: 20 article-title: Mechanisms of action of and resistance to ciprofloxacin publication-title: Am J Med – volume: 53 start-page: 664 issue: 9 year: 2003 end-page: 667 article-title: Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers publication-title: Arzneimittelforschung – volume: 6 start-page: 87 issue: 2 year: 1986 end-page: 91 article-title: Pharmacokinetics of ciprofloxacin in elderly subjects publication-title: Pharmacotherapy: the Journal of Human Pharmacology and Drug Therapy – volume: 123 start-page: 1661 issue: 15 year: 2011 end-page: 1670 article-title: Pharmacogenomics publication-title: Circulation – volume: 6 start-page: 119 issue: 2 year: 1995 end-page: 122 article-title: Absorption of ciprofloxacin in febrile and afebrile patients publication-title: Int J Antimicrob Agents – volume: 36 start-page: 830 issue: 4 year: 1992 end-page: 832 article-title: Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin publication-title: Antimicrob Agents Chemother – volume: 14 start-page: S196 issue: S3 year: 1986 end-page: S202 article-title: The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin publication-title: Infection – volume: 57 start-page: 446 issue: 4 year: 1995 end-page: 454 article-title: Pharmacokinetics and pharmacodynamics of neutrophil‐associated ciprofloxacin in humans publication-title: Clinical Pharmacology & Therapeutics – volume: 15 start-page: 545 issue: 1 year: 2015 article-title: Ciprofloxacin resistance in community‐ and hospital‐acquired Escherichia coli urinary tract infections: a systematic review and meta‐analysis of observational studies publication-title: BMC Infect Dis – volume: 47 start-page: 3789 issue: 12 year: 2003 end-page: 3794 article-title: Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose publication-title: Antimicrob Agents Chemother – volume: 12 start-page: 45 issue: 1 year: 2023 article-title: Mapping reviews, scoping reviews, and evidence and gap maps (EGMs): the same but different— the "big picture" review family publication-title: Syst Rev – volume: 28 start-page: 691 issue: 8 year: 1988 end-page: 699 article-title: Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis publication-title: The Journal of Clinical Pharmacology – volume: 25 start-page: 3843 issue: 17 year: 2020 article-title: Activity of antimicrobial peptides and ciprofloxacin against biofilms publication-title: Molecules – volume: 46 start-page: 3724 issue: 12 year: 2002 end-page: 3730 article-title: Target site concentrations of ciprofloxacin after single intravenous and oral doses publication-title: Antimicrob Agents Chemother – volume: 4 start-page: 1 issue: 1 year: 2018 end-page: 2 article-title: Mucormycosis: new actor in the saga of COVID‐19 publication-title: Journal of Current Research in Scientific Medicine – volume: 29 start-page: 62 issue: 1 year: 1986 end-page: 66 article-title: Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses publication-title: Antimicrob Agents Chemother – volume: 33 start-page: 109 issue: 1 year: 2020 end-page: 113 article-title: Pharmacodynamics and pharmacokinetics in older adults publication-title: Current Opinion in Anesthesiology – volume: 35 start-page: 1004 issue: 5 year: 1991 end-page: 1007 article-title: Effect of staggered dose of calcium on the bioavailability of ciprofloxacin publication-title: Antimicrob Agents Chemother – volume: 51 start-page: 268 issue: 3 year: 2020 end-page: 277 article-title: Oral ciprofloxacin pharmacokinetics in healthy Mexican volunteers and other populations: is there interethnic variability? publication-title: Arch Med Res – volume: 9 issue: 6 year: 2021 article-title: Elucidating the Antimycobacterial mechanism of action of ciprofloxacin using metabolomics publication-title: Microorganisms – volume: 17 start-page: 629 issue: 5 year: 1986 end-page: 635 article-title: Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients publication-title: Journal of Antimicrobial Chemotherapy – start-page: 55 year: 1986 end-page: 58 – volume: 58 start-page: 265 issue: 2 year: 2004 end-page: 278 article-title: Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system publication-title: Eur J Pharm Biopharm – volume: 154 start-page: 383 issue: 2 year: 2018 end-page: 393 article-title: Ion Channel modulators in cystic fibrosis publication-title: Chest – volume: 32 start-page: 168 issue: 3 year: 2011 end-page: 174 article-title: Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers publication-title: Biopharm Drug Dispos – volume: 122 start-page: 186 year: 2018 end-page: 196 article-title: An in silico approach to determine challenges in the bioavailability of ciprofloxacin, a poorly soluble weak base with borderline solubility and permeability characteristics publication-title: Eur J Pharm Biopharm – year: 2023 – volume: 35 start-page: 2352 issue: 11 year: 1991 end-page: 2358 article-title: Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers publication-title: Antimicrob Agents Chemother – volume: 49 start-page: 346 issue: Supplement 2 year: 1995 end-page: 348 article-title: The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers publication-title: Drugs – volume: 169 start-page: 467 issue: 7 year: 2018 end-page: 473 article-title: PRISMA extension for scoping reviews (PRISMA‐ScR): checklist and explanation publication-title: Ann Intern Med – volume: 42 start-page: 1797 issue: 11 year: 2016 end-page: 1800 article-title: Understanding PK/PD publication-title: Intensive Care Med – volume: 371 start-page: 106 issue: 1‐2 year: 2009 end-page: 113 article-title: Solubility behavior and biopharmaceutical classification of novel high‐solubility ciprofloxacin and norfloxacin pharmaceutical derivatives publication-title: Int J Pharm – volume: 32 start-page: 505 issue: 6 year: 2008 end-page: 510 article-title: Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches publication-title: Int J Antimicrob Agents – volume: 31 start-page: 257 issue: 3 year: 1991 end-page: 261 article-title: Clinical and chemical interactions between iron preparations and ciprofloxacin publication-title: Br J Clin Pharmacol – volume: 39 start-page: 2161 issue: 9 year: 1995 end-page: 2163 article-title: Absorption of ciprofloxacin in patients with diabetic gastroparesis publication-title: Antimicrob Agents Chemother – volume: 9 start-page: 377 issue: 6 year: 1989 end-page: 380 article-title: The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin publication-title: Pharmacotherapy – volume: 39 start-page: 1045 issue: 5 year: 1995 end-page: 1049 article-title: Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics publication-title: Antimicrob Agents Chemother – volume: 10 year: 2021 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: Syst Rev – volume: 27 start-page: 375 issue: 3 year: 1985 end-page: 379 article-title: Pharmacokinetics of ciprofloxacin after oral and parenteral administration publication-title: Antimicrob Agents Chemother – year: 2013 – ident: e_1_2_11_44_1 doi: 10.2165/00044011‐200929040‐00006 – ident: e_1_2_11_55_1 doi: 10.1128/AAC.29.1.62 – ident: e_1_2_11_8_1 doi: 10.1016/j.ijpharm.2008.12.026 – ident: e_1_2_11_76_1 doi: 10.1016/j.ijantimicag.2008.05.019 – ident: e_1_2_11_83_1 doi: 10.1038/psp.2013.14 – ident: e_1_2_11_59_1 doi: 10.1016/j.ijantimicag.2006.07.026 – ident: e_1_2_11_12_1 doi: 10.3389/fpubh.2022.1025633 – ident: e_1_2_11_34_1 doi: 10.1093/jac/33.1.103 – ident: e_1_2_11_57_1 doi: 10.1007/978‐3‐663‐01930‐5_17 – ident: e_1_2_11_84_1 doi: 10.1016/j.coph.2017.09.009 – ident: e_1_2_11_39_1 doi: 10.1016/S0399‐077X(05)81021‐2 – ident: e_1_2_11_52_1 doi: 10.1007/BF00606636 – ident: e_1_2_11_19_1 doi: 10.46658/JBIRM‐20‐01 – ident: e_1_2_11_66_1 doi: 10.1093/jac/20.4.575 – ident: e_1_2_11_56_1 doi: 10.1016/j.arcmed.2020.02.008 – ident: e_1_2_11_46_1 doi: 10.1111/j.1365‐2125.1991.tb05526.x – ident: e_1_2_11_47_1 doi: 10.1002/j.1875‐9114.1986.tb03458.x – ident: e_1_2_11_75_1 doi: 10.1016/j.exger.2014.05.013 – ident: e_1_2_11_22_1 doi: 10.1007/s40262‐015‐0236‐8 – ident: e_1_2_11_69_1 doi: 10.1128/AAC.41.7.1508 – ident: e_1_2_11_62_1 doi: 10.1097/ACO.0000000000000814 – ident: e_1_2_11_65_1 doi: 10.1128/AAC.35.7.1484 – ident: e_1_2_11_54_1 doi: 10.1128/AAC.39.5.1045 – ident: e_1_2_11_7_1 doi: 10.1002/jps.22259 – ident: e_1_2_11_60_1 doi: 10.1128/AAC.35.11.2352 – ident: e_1_2_11_68_1 doi: 10.1093/jac/26.suppl_B.61 – ident: e_1_2_11_20_1 doi: 10.7326/M18‐0850 – ident: e_1_2_11_77_1 doi: 10.1093/jac/dkr220 – ident: e_1_2_11_11_1 doi: 10.1016/j.ejpb.2017.10.019 – ident: e_1_2_11_23_1 doi: 10.1186/s13643‐023‐02178‐5 – volume: 47 start-page: 214 issue: 3 year: 2004 ident: e_1_2_11_30_1 article-title: Single‐dose pharmacokinetics study of ciprofloxacin after oral administration to the healthy volunteers publication-title: Biological Sciences—PJSIR – ident: e_1_2_11_48_1 doi: 10.1128/AAC.35.5.1004 – ident: e_1_2_11_81_1 doi: 10.1007/s13181‐015‐0488‐6 – ident: e_1_2_11_5_1 doi: 10.3390/microorganisms9061158 – volume: 53 start-page: 664 issue: 9 year: 2003 ident: e_1_2_11_38_1 article-title: Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers publication-title: Arzneimittelforschung – ident: e_1_2_11_41_1 doi: 10.1128/AAC.31.5.709 – ident: e_1_2_11_42_1 doi: 10.1128/AAC.26.5.741 – ident: e_1_2_11_82_1 doi: 10.1007/s00134‐015‐4032‐6 – ident: e_1_2_11_45_1 doi: 10.1128/AAC.37.10.2193 – ident: e_1_2_11_43_1 doi: 10.1128/AAC.27.3.375 – ident: e_1_2_11_49_1 doi: 10.1002/j.1875‐9114.1989.tb04152.x – ident: e_1_2_11_32_1 doi: 10.1128/AAC.46.12.3724‐3730.2002 – ident: e_1_2_11_37_1 doi: 10.1093/jac/33.1.111 – ident: e_1_2_11_80_1 doi: 10.1093/jac/dkab275 – ident: e_1_2_11_25_1 doi: 10.1111/j.1365‐2125.1996.tb00059.x – ident: e_1_2_11_40_1 doi: 10.1128/AAC.36.4.830 – ident: e_1_2_11_29_1 doi: 10.1093/jac/17.5.629 – ident: e_1_2_11_51_1 doi: 10.1128/AAC.38.9.2187 – ident: e_1_2_11_27_1 doi: 10.1038/clpt.1991.174 – volume-title: Ciprofloxacin. StatPearls year: 2023 ident: e_1_2_11_2_1 – ident: e_1_2_11_13_1 doi: 10.1186/s12879‐015‐1282‐4 – ident: e_1_2_11_50_1 doi: 10.1016/0924‐8579(95)00030‐6 – ident: e_1_2_11_33_1 doi: 10.1016/0009‐9236(95)90215‐5 – ident: e_1_2_11_78_1 doi: 10.1093/jac/dky485 – ident: e_1_2_11_28_1 doi: 10.1002/j.1552‐4604.1989.tb03260.x – ident: e_1_2_11_67_1 doi: 10.1002/j.1552‐4604.1988.tb03202.x – ident: e_1_2_11_73_1 doi: 10.3390/pharmaceutics14050965 – ident: e_1_2_11_63_1 doi: 10.1128/AAC.30.1.152 – ident: e_1_2_11_9_1 doi: 10.1023/A:1016212804288 – ident: e_1_2_11_21_1 – ident: e_1_2_11_16_1 doi: 10.1097/FPC.0b013e32834c6efd – ident: e_1_2_11_24_1 doi: 10.1186/s13643-021-01626-4 – ident: e_1_2_11_58_1 doi: 10.1128/AAC.47.12.3789‐3794.2003 – volume: 82 start-page: 12 issue: 4 year: 1987 ident: e_1_2_11_3_1 article-title: Mechanisms of action of and resistance to ciprofloxacin publication-title: Am J Med – volume-title: Cochrane handbook for systematic reviews of interventions version 6.3 year: 2022 ident: e_1_2_11_18_1 – ident: e_1_2_11_4_1 doi: 10.3109/14756360903373350 – ident: e_1_2_11_36_1 doi: 10.1128/AAC.31.6.915 – ident: e_1_2_11_10_1 doi: 10.1016/j.ejpb.2004.03.001 – ident: e_1_2_11_61_1 doi: 10.1007/BF01667843 – ident: e_1_2_11_35_1 doi: 10.1128/AAC.24.5.784 – ident: e_1_2_11_15_1 doi: 10.1161/CIRCULATIONAHA.109.914820 – ident: e_1_2_11_71_1 doi: 10.1016/j.chest.2018.04.036 – ident: e_1_2_11_74_1 doi: 10.1016/j.accpm.2022.101080 – ident: e_1_2_11_70_1 doi: 10.1128/AAC.39.9.2161 – ident: e_1_2_11_72_1 doi: 10.1007/s00228‐020‐02873‐5 – ident: e_1_2_11_79_1 doi: 10.3390/pharmaceutics13081156 – ident: e_1_2_11_14_1 doi: 10.4103/jcrsm.jcrsm_8_18 – ident: e_1_2_11_17_1 doi: 10.1016/j.ejps.2017.01.030 – ident: e_1_2_11_53_1 doi: 10.1002/bdd.748 – ident: e_1_2_11_26_1 doi: 10.2165/00003495‐199500492‐00094 – ident: e_1_2_11_64_1 doi: 10.1002/j.1552‐4604.1986.tb02938.x – ident: e_1_2_11_6_1 doi: 10.3390/molecules25173843 – ident: e_1_2_11_85_1 doi: 10.1093/jac/dkq211 – ident: e_1_2_11_31_1 doi: 10.1159/000195216 |
| SSID | ssj0013165 |
| Score | 2.4519386 |
| SecondaryResourceType | review_article |
| Snippet | Aims
To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations.
Methods
A scoping review... To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations. A scoping review was... To map the literature on oral ciprofloxacin's pharmacokinetics and its implications for dose adjustments in specific populations.AIMSTo map the literature on... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 528 |
| SubjectTerms | Adult Aged Ciprofloxacin Humans pharmacokinetics PK/PD popPK Renal Replacement Therapy scoping review |
| Title | Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.15933 https://www.ncbi.nlm.nih.gov/pubmed/37850318 https://www.proquest.com/docview/2878711956 |
| Volume | 90 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEF6kT754H_ViFREfmmKOzaFPVZRSUIpY6IMQZo-AWNJiWrD-emdytJ4gQh6SMNlsdnZ2ZrIz3zB2jB6Dr1y03OxEacsLhbTAdqSlwQlQoQsd2ZQ7fHvnt3tepy_6C-yiyoUp8CFmP9xIMvL1mgQcZPZByKUaNVEXu4T0SbFaZBDdO_MdBDsvI0kmMTpbwi5RhSiKZ_bkZ130zcD8bK_mCudmmT1WXS3iTJ6bk7FsqrcvKI7__JYVtlQaorxVzJxVtmDSNXbSLZCspw3-ME_Myhr8hHfnGNfTddapLp_x3UTChwmnZH-unqgM-GD4Cuop5XjkCB-8xG_NznmLUyYMakxepM1ssN7N9cNV2yrLMljK9SmSLVLCB_BEEoJnyzDQ6MeB40ipjTYQJtozAS4NSRLpIHBBnwkASISWES6myribrJYOU7PNOHhuEmoVBbYATwspZRT6eMs2Z0qA8uvstGJQrErMciqdMYgr3wVHLs5Hrs6OZqSjAqjjJ6LDissxihHtjUBqhpMsRscRXUdKnqyzrYL9s2bcIBS09mFvcib-3n58edXNT3b-TrrLFh00lIpI8D1WG79MzD4aOmN5kM_odylg-pU |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEB6qPuiL91HPVUR8MKU5Nof4oqJUrVKkgi8S9gqUlrTYFtRf7-wmaT1BhDwkYZJsdnZ2ZnZnvgHYR4_BFy5abnYipOWFlFvMdrglmROgQqcysnXu8O2dX3vwrh_pYwlOilyYDB9itOCmJcPM11rA9YL0BynnoldBZey6EzClK3obh-reGe8h2KaQpDaK0d2ido4rpON4Ro9-1kbfTMzPFqtROZdz8FQ0Nos0aVeGA14Rb19wHP_7N_Mwm9ui5DQbPAtQUukiHDQyMOvXI9Ic52b1j8gBaYxhrl-X4Lq4bOPHNQnpJkTn-xPR0pXAO90XJlopwcOAfJAcwrV_TE6JToZBpUmyzJlleLi8aJ7XrLwygyVcXwezRYL6jHk0CZln8zCQ6Moxx-FcKqlYmEhPBTg7JEkkg8BlskoZYwmVPML5VCh3BSbTbqrWgDDPTUIposCmzJOUcx6FPt6yVVVQJvwyHBYcikUOW66rZ3Tiwn3BnotNz5Vhb0Tay7A6fiLaLdgcoyTp7RGWqu6wH6PviN6jzp8sw2rG_9Fr3CCkevrD1hgu_v7--Oy8YU7W_066A9O15m09rl_d3WzAjIN2UxYYvgmTg-eh2kK7Z8C3zfB-B8Si_rA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEB60gvjifdRzFREfTGmOzaFPXsWbIgo-CGFPKC1psS1Yf72zOVpPECEPSZhsNjs7OzPZmW8AdtFj8IWLlputhbS8kHKL2Q63JHMCVOhURrbJHb698y8evasn-jQGR0UuTIYPMfzhZiQjXa-NgHek_iDkXHQqqItddxwmPL8amil9du-MthDstI6ksYnR26J2DitkwniGj35WRt8szM8Ga6pxajPwXPQ1CzRpVvo9XhFvX2Ac__kxszCdW6LkOJs6czCmknnYq2dQ1oMD8jDKzOoekD1SH4FcDxbgqrhs4rsNCWlrYrL9iWiYOuCt9isTjYTgkUJ8kBzAtXtIjolJhUGVSbK8mUV4rJ0_nF5YeV0GS7i-CWWLBPUZ86gOmWfzMJDoyDHH4VwqqViopacCXBu0jmQQuExWKWNMU8kjXE2FcpeglLQTtQKEea4OpYgCmzJPUs55FPp4y1ZVQZnwy7BfMCgWOWi5qZ3RigvnBUcuTkeuDDtD0k6G1PET0XbB5RjlyGyOsES1-90YPUf0HU32ZBmWM_YPm3GDkJrFD3uTMvH39uOT03p6svp30i2YrJ_V4pvLu-s1mHLQaMqiwteh1Hvpqw00enp8M53c7-4R_Wg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+oral+ciprofloxacin+in+adult+patients%3A+A+scoping+review&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Junkert%2C+Allan+Michael&rft.au=Lazo%2C+Raul+Edison+Luna&rft.au=Deffert%2C+Fl%C3%A1via&rft.au=Carneiro%2C+Jaqueline&rft.date=2024-02-01&rft.issn=1365-2125&rft.eissn=1365-2125&rft.volume=90&rft.issue=2&rft.spage=528&rft_id=info:doi/10.1111%2Fbcp.15933&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |